Guidelines for hospital-acquired pneumonia and health-care-associated pneumonia: A vulnerability, a pitfall, and a fatal flaw

The Lancet Infectious Diseases

Volumn 11, Issue 3, 2011, Pages 248-252

  Yu, Victor L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; COMBINATION CHEMOTHERAPY; DIAGNOSTIC ACCURACY; DRUG INDICATION; DRUG USE; EMPIRICISM; HOSPITAL INFECTION; HUMAN; MONOTHERAPY; MORTALITY; NOTE; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; HUMANS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC;

EID: 79952014249     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70005-6     Document Type: Note

References (37)

1. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. American Thoracic Society, Infectious Diseases Society of AmericaInfectious Diseases Society of America.
2. Mandell LA, Wunderink RG, Anqueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72.
3. Venditti M, Falcone M, Corrao S, Licata G, Serra P Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009, 150:19-26.
4. Seymann GB, Di Francesco L, Sharpe B, et al. The HCAP gap: differences between self-reported practice patterns and published guidelines for health care-associated pneumonia. Clin Infect Dis 2009, 49:1868-1874.
5. Fujitani S, Yu VL A new category-healthcare-associated pneumonia: a good idea, but problems with its execution. Eur J Clin Microbiol Infect Dis 2006, 25:627-631.
6. Ewig S, Welte T, Chastre J, Torres A Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010, 10:279-287.
7. Kett DH, Cano E, Quartin AA, et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 2011, 11:181-189. the Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators.
8. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990, 69:307-316.
9. Fine MJ, Orloff JJ, Arisumi D, et al. Prognosis of patients hospitalized with community-acquired pneumonia. Am J Med 1990, 88:1N-8N.
10. Marston BJ, Plouffe JF, File TM, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997, 157:1709-1718.
11. Sopena N, Sabria M, Pedro-Botet ML, et al. Prospective study of community-acquired pneumonia of bacterial etiology in adults. Eur J Clin Microbiol Infect Dis 1999, 18:852-858.
12. Mundy LM, Auwaerter PG, Oldach D, et al. Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med 1995, 152:1309-1315.
13. Vergis EN, Yu VL New directions for future studies of community-acquired pneumonia optimizing impact on patient care. Eur J Clin Microbiol Infect Dis 1999, 18:847-851.
14. Fujitani S, Sun HY, Yu VL, Weingarten JA. Pneumonia due to Pseudomonas aeruginosa. Part I: epidemiology, clinical diagnosis and source. Chest (in press).
15. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000, 132:621-630.
16. Niederman MS The argument against using quantitative cultures in clinical trials and for the management of ventilator-associated pneumonia. Clin Infect Dis 2010, 51(suppl 1):S93-S99.
17. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162:505-511.
18. Aarts MA, Brun-Buisson C, Cook DJ, et al. Antibiotic management of suspected nosocomial ICU-acquired infection: does prolonged empiric therapy improve outcome?. Intensive Care Med 2007, 33:1369-1378.
19. Zhou H, Yang K, Lynch SV, et al. Increased mortality of ventilated patients with endotracheal Pseudomonas aeruginosa without clinical signs of infection. Crit Care Med 2008, 36:2495-2503.
20. Flanagan JL, Brodie EL, Weng L, et al. Loss of bacterial diversity during antibiotic treatment of intubated patients colonized with Pseudomonas aeruginosa. J Clin Microbiol 2007, 45:1954-1962.
21. Kollef MH, Morrow LE, Baughman RP, et al. Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes-proceedings of the HCAP Summit. Clin Infect Dis 2008, 46(suppl 4):S296-S334.
22. Brito V, Niederman MS Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis 2009, 22:316-325.
23. Bergmans DCJJ, Bonten MJM, Mayhall CG Nosocomial pneumonia. Hospital epidemiology and infection control 2004, 311-339. Lippincott Williams and Wilkins, Philadelphia, PA, USA.
24. Singh N, Falestiny MN, Rogers P, et al. Pulmonary infiltrates in the surgical ICU: prospective assessment of predictors of etiology and mortality. Chest 1998, 114:1129-1136.
25. Baum SG, Kaltsas A Guideline tyranny: primum non nocere. Clin Infect Dis 2008, 46:1879-1880.
26. Friedberg MW, Mehrotra A, Linder JA Reporting hospitals' antibiotic timing in pneumonia: adverse consequences for patients?. Am J Manag Care 2009, 15:137-144.
27. Yu VL, Stout JE Rapid diagnostic testing for community-acquired pneumonia: can innovative technology for clinical microbiology be exploited?. Chest 2009, 136:1618-1621.
28. Johansson NKM, Tiveljung-Lindell A, Giske CG, Hedlund J Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010, 50:202-209.
29. Leggieri N, Rida A, Francois P, Schrenzel J Molecular diagnosis of bloodstream infections: planning to (physically) reach the bedside. Curr Opin Infect Dis 2010, 23:311-319.
30. Kruger S, Ewig S, Papassotiriou J, et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009, 10:65.
31. Schuetz P, Batschwaroff M, Dusemund F, et al. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur J Clin Microbiol Infect Dis 2010, 29:269-277.
32. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004, 350:451-458.
33. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007, 51:3568-3573.
34. Silvestri L, van Saene HK, de la Cal MA, Gullo A Adult hospital and ventilator-associated pneumonia guidelines: eminence- rather than evidence-based. Am J Respir Crit Care Med 2006, 173:131-133.
35. Maruyama T, Niederman MS, Kobayashi T, et al. A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly. Respir Med 2008, 102:1287-1295.
36. Ramirez JA Fostering international multicenter collaborative research: the CAPO Project. Int J Tuberc Lung Dis 2007, 11:1062-1065.
37. Sun HY, SFujitani HY, Quintiliani R, Yu VL. Pneumonia due to Pseudomonas aeruginosa, part II: antimicrobial resistance, pharmacodynamic concepts and antibiotic therapy. Chest (in press).